Aethon Therapeutics launched Jan. 9 with $25 million in funding from venture capital firm Apple Tree Partners and another $5 million from funders including NYU Langone Health, which has equity in the company. Aethon aims to create novel antibodies that overcome drug resistance by boosting immunity and identifying and eliminating cancer cells.
“We are excited to be part of new efforts in the field to improve and extend the effects of targeted therapy and prevent resistance and relapse,” said Shohei Koide, PhD, a researcher at NYU Langone Health’s Perlmutter Cancer Center and an inventor of Aethon’s drug discovery platform, in a Jan. 9 Aethon news release. “By uniting immunotherapy and targeted therapy in this way, we hope to amplify the power of both.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
